Translational Xenograft Platforms for CAR-T Cell Therapy Evaluation
Including PDX and CD19 Targeting
CAR-T therapies target specific tumor-associated antigens. Our preclinical Patient-Derived Xenograft (PDX) in vivo CAR-T evaluation Translational Platform allows rapid target selection from a vast array of antigens expressed by models derived from patients, which truly mimic human disease and immunotherapy response.
Why PDX for CAR-T Therapy Evaluation?
- 2,500 well-characterized models providing a wide range of CAR-T therapy targets
- Highly predictive PDX models, preserving the heterogeneous pathological and genetic characteristics of the original patient tumors, providing a translatable response
- Quickly and easily find models overexpressing your antigen of interest from our curated online model characterization database (HuBase™) and new search engine OncoExpress™
Is CD19 Your CAR-T Therapy Target?
Need a validated model for CD19 - the main target for CAR-T therapies in hematological malignancies?
Our validated Raji human Burkitt lymphoma, CD19 positive xenograft model is highly sensitive to CD19 targeting, and ready to run your efficacy studies now.
Contact us today for expert advice on progressing your preclinical CAR-T therapy studies into the clinic.